LRP5

Across TCGA pan-cancer cohorts, LRP5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LRP5 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher LRP5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRP5 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CESC, BLCA, and READ are the cancer types where LRP5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	III,IV	0.079	0.768	<.001	32	view →
BLCA	DFS	Median	All	0.340	0.635	<.001	23	view →
READ	OS	Median	All	0.156	0.692	.002	12	view →
ESCA	OS	Median	II,III,IV	0.277	0.686	.026	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	All	1.000	0.657	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LRP5–CESC (OS)

Open the CESC breakdown →